Physician profile
Jared C Robins
NPI 1124063383
$8,295.66
in general payments reported to CMS, 2019-2025
7 companies · $53.20 in 2025
The $53.20 reported for 2025 was less than what a typical Reproductive Endocrinology provider received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $6,497 · 2022: $813 · 2024: $933 · 2025: $53.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $831 · Food and Beverage: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $831.32 |
| Food and Beverage | $154.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring International Center Sa | $5,729.31 | 2021 | |
| Ferring Pharmaceuticals INC. | $1,053.53 | 2021-2025 | |
| Ibsa Institut Biochimique Sa | $621.20 | 2022 | |
| Coopersurgical, INC. | $479.54 | 2021-2022 | |
| Organon LLC | $221.59 | 2021 | |
| Emd Serono, INC. | $190.49 | 2021-2024 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Robins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.